0001387131-20-001050.txt : 20200205 0001387131-20-001050.hdr.sgml : 20200205 20200205180708 ACCESSION NUMBER: 0001387131-20-001050 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200203 FILED AS OF DATE: 20200205 DATE AS OF CHANGE: 20200205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Krassan Mitchell CENTRAL INDEX KEY: 0001532232 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-00100 FILM NUMBER: 20580182 MAIL ADDRESS: STREET 1: 951 BROKEN SOUND PARKWAY NW STREET 2: SUITE 320 CITY: BOCA RATON STATE: FL ZIP: 33487 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TherapeuticsMD, Inc. CENTRAL INDEX KEY: 0000025743 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870233535 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-961-1900 MAIL ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: AMHN, Inc. DATE OF NAME CHANGE: 20090930 FORMER COMPANY: FORMER CONFORMED NAME: CROFF ENTERPRISES INC DATE OF NAME CHANGE: 19970915 FORMER COMPANY: FORMER CONFORMED NAME: CROFF OIL CO DATE OF NAME CHANGE: 19920703 4 1 krassan-form4_020320.xml OWNERSHIP DOCUMENT X0306 4 2020-02-03 0 0000025743 TherapeuticsMD, Inc. TXMD 0001532232 Krassan Mitchell 951 YAMATO ROAD, SUITE 220 BOCA RATON FL 33431 0 1 0 0 Chief Strategy Officer Common Stock 2020-02-03 4 M 0 105703 0.1874 A 105703 D Common Stock 2020-02-03 4 M 0 194297 0.2037 A 300000 D Common Stock 2020-02-03 4 S 0 300000 2.2564 D 0 D Non-Qualified Stock Option (right to buy) 0.1874 2020-02-03 4 M 0 105703 0 D 2011-05-01 2020-05-01 Common Stock 105703 0 D Non-Qualified Stock Option (right to buy) 0.2037 2020-02-03 4 M 0 194297 0 D 2013-09-01 2020-09-01 Common Stock 194297 489658 D The sales were made pursuant to the Reporting Person's 10b5-1 trading plan dated December 10, 2019 with respect to shares of common stock underlying options to purchase common stock that expire on or before September 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.285, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Mitchell Krassan 2020-02-05